A preferable solution to the HIV/AIDS global pandemic is an effective vaccine. A major priority for HIV-1 vaccine development is to identify an immunogen that can elicit high titers of neutralizing antibody (nAb) against the envelope glycoprotein (Env) spikes on circulating primary viruses. The functional (native) form of Env on the surface of virions and infected cells is a gp120-gp41 heterotrimer. A critical barrier in eliciing HIV-1 nAb is not one of eliciting anti-Env Ab in general, but rather that anti-Env responses are disproportionately elicited to irrelevant forms of Env and its subunits, rather than to the native Env trimer. Factors that likely contribute to the elicitation of weak and/or isolate specific nAb responses to HIV immunogens are sequence variability and heterogeneity in Env, as well as lability and low copy number of the trimeric, native form that is found on membrane surfaces. The goal of this project is to identify, characterize and develop virus-like particles (VPs or VLPs immunogens that display Env trimers that are more stable, more homogeneously native and in higher copy number than that of wild-type HIV-1. From diverse Env libraries created using DNA recombination methods Env VPs will be subjected to a variety of destabilizing conditions and then selected for binding to trimer-specific nAbs and nAb precursors in native and receptor-activated conformations while counter-screening against non-neutralizing Abs. To identify VPs with improved yield and native Env trimer content, we will engineer and select from diverse gp41 cytoplasmic tail and Gag libraries, again using nAbs. We will immunize rabbits using selected VLPs with stable, high copy number Env trimers and determine serum nAb titers against related strains and heterologous isolates in HIV-1 neutralization assays. We will probe lead Env immunogens using serum Ab and a panel of mAbs in a variety of binding and neutralization assays to ascertain the extent of antigenic mimicry of wildtype Env trimers. Detailed molecular characterization of the stable Env trimers and antisera should allow further optimization of lead immunogens and immunization regimens to elicit crossreactive nAb responses against different primary isolates of HIV-1. We expect the proposed studies to positively contribute to the development of an Env trimer-based vaccine.
An HIV/AIDS vaccine should stimulate effective antibody responses against the virus. Here we will attempt to elicit such neutralizing antibody in animals using virus-like particles that are selected to display a greater number of specific antibody targets and with high stabilities.
|Ingale, Jidnyasa; Stano, Armando; Guenaga, Javier et al. (2016) High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. Cell Rep 15:1986-99|
|Lee, Jeong Hyun; Leaman, Daniel P; Kim, Arthur S et al. (2015) Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nat Commun 6:8167|
|Leaman, Daniel P; Lee, Jeong Hyun; Ward, Andrew B et al. (2015) Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes. J Virol 89:6725-45|
|Kim, Arthur S; Leaman, Daniel P; Zwick, Michael B (2014) Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization. PLoS Pathog 10:e1004271|
|Falkowska, Emilia; Le, Khoa M; Ramos, Alejandra et al. (2014) Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40:657-68|